Salivary Oxytocin as a Biomarker of Psychedelic Treatment
NCT07345858 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2026-01-16
Summary
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Conditions
- Major Depressive Disorder (MDD)
Sponsors & Collaborators
-
University of Geneva, Switzerland
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-05
- Primary Completion
- 2026-07-31
- Completion
- 2026-10-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
NCT05399498 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression
NCT03756246 ·Status: UNKNOWN ·Phase: PHASE4
-
An Exploratory Study Examining Biopsychosocial Markers of Anxiety and Depression
NCT05466851 ·Status: RECRUITING
-
Stress and the Sympathetic Nervous System in Adults With Depression
NCT04838262 ·Status: COMPLETED ·Phase: NA
-
Acupuncture in Depression: From the Clinical Trial, Biomarkers to Molecular Biology
NCT03452384 ·Status: COMPLETED ·Phase: NA
-
Psilocybin in Depression Resistant to Standard Treatments
NCT04959253 ·Status: UNKNOWN ·Phase: PHASE2
-
Speech-based Digital Biomarker for Psychiatric Disease
NCT04851912 ·Status: UNKNOWN
-
A Randomized Neuroimaging Trial of Psilocybin in Depression
NCT06072898 ·Status: RECRUITING ·Phase: PHASE2
-
Investigating Biological Markers, Targets, and Intervention for Mood Disorders
NCT04632498 ·Status: TERMINATED ·Phase: NA
-
Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study
NCT03523767 ·Status: TERMINATED ·Phase: PHASE1
-
Vocal Acoustic Biomarkers in Depression
NCT00844948 ·Status: COMPLETED
-
Inflammatory Markers and Resistant Depression
NCT02847533 ·Status: UNKNOWN ·Phase: NA
-
Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression
NCT06174285 ·Status: RECRUITING ·Phase: NA
-
A Neurobiological Model of Anhedonia
NCT05629520 ·Status: COMPLETED
-
PKC as Serum Biomarkers for Depression
NCT04531423 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
NCT07258485 ·Status: RECRUITING
-
Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder
NCT00229398 ·Status: COMPLETED
-
Impact of Immune Challenge on Triple Network Connectivity in Humans
NCT02653235 ·Status: UNKNOWN ·Phase: NA
-
Neurobiological Effects of Light on MDD
NCT02940769 ·Status: TERMINATED ·Phase: NA
-
Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine
NCT06630065 ·Status: RECRUITING ·Phase: NA
-
Rhythm and Depression
NCT02857036 ·Status: UNKNOWN ·Phase: NA
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
NCT04582916 ·Status: RECRUITING ·Phase: PHASE1
-
Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862
NCT04682769 ·Status: COMPLETED
-
Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment
NCT02523105 ·Status: COMPLETED ·Phase: NA
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
NCT07166289 ·Status: RECRUITING ·Phase: NA